By Michael S. Rosenwald Thomas S. Langner, a sociologist who helped lead a landmark study of New Yorkers that revealed striking insights about the social, cultural and economic forces that shape mental illness, died on March 16 at his home in Sandy Hook, Conn. He was 102. His wife, Susan Kassirer, confirmed the death. When “Mental Health in the Metropolis: The Midtown Manhattan Study” was published in 1962, headline writers had a field day with the top-line finding: that only 18.5 percent of Manhattan residents could be considered psychologically well adjusted, while 23 percent showed significant impairment in daily functioning. “City Gets Mental Test, Results Are Real Crazy,” Newsday declared. The Daytona Beach Morning Journal wondered: “New York Living for ‘Nuts’ Only?” The actual substance of the two-part study — the second installment appeared in 1963 — was the challenge it posed to the widely held view in psychiatry that biological and individual factors are the primary drivers of mental illness. Professor Langner, along with a team of psychiatrists, anthropologists and social workers at Cornell University Medical College (now Weill Cornell Medicine), spent more than a decade studying 1,660 people who lived on the East Side of Manhattan, between 59th and 96th Streets. The researchers concluded that developing mental illness didn’t simply come down to a genetic lottery. © 2026 The New York Times Company

Keyword: Stress; Schizophrenia
Link ID: 30198 - Posted: 04.15.2026

By Ellen Barry When Cohen Miles-Rath walks into his father’s house, the history of his psychosis is right there in front of him. There is the place where he was standing when he received a cryptic message on his phone: The devil had entered his father’s body. There is the drawer where he spotted a knife whose handle was white — the color of God! There is the floor where, as they grappled over the knife, Cohen bit off part of his father’s earlobe, and blood spattered over both of them. There is the spot where, pinned to the floor, Cohen reached up with the knife and slashed wildly at his father’s throat. The violence lasted seconds but changed his whole life. With voices still racketing in his head, Cohen found himself in jail, facing charges of second-degree assault and criminal mischief, felonies punishable by up to 10 years in prison. Stunned and bleeding, his father had pressed charges, and taken out a restraining order against him. But Cohen hadn’t killed him. In the years that followed, he had the feeling that he had walked right up to the edge of a chasm. About 300 times a year in the United States, a child kills a parent, making up around 2 percent of all homicides. A large portion of these cases involve people like Cohen: young men with severe mental illness who are living at home. When mounting symptoms of psychosis make school or work impossible, parents are the support system of last resort. Paranoid delusions can cruelly invert that logic, turning people against the figure closest to them. © 2026 The New York Times Company

Keyword: Schizophrenia; Aggression
Link ID: 30186 - Posted: 04.01.2026

By Trip Gabriel Dr. Judith L. Rapoport, a child psychiatrist who brought public awareness to obsessive-compulsive disorder with her best-selling 1989 book, “The Boy Who Couldn’t Stop Washing,” based on her groundbreaking research into the condition’s causes and treatment, died on March 7 in Washington, D.C. She was 92. Her death, at a retirement home, was from lung cancer, her husband, Stanley Rapoport, said. Dr. Rapoport’s book about obsessive-compulsive disorder, written in an engaging style for nonscientific readers, clarified that the condition was far more common than generally thought, affecting some 1 to 3 percent of the population. The disorder had long remained in the shadows because of the shame that surrounded its symptoms, which could include habits like checking and rechecking that appliances were off, performing counting rituals before doing something as simple as walking through a doorway, or scrubbing hands with soap and water until the skin was raw — any of which, uncontrollably repeated, might waste hours of the day. Dr. Rapoport showed that there was a neurological basis for obsessions, or intrusive repetitive thoughts, and also for their linked compulsions, or pointless rituals of behavior. Along with other researchers in the 1980s, she upended the received psychiatric wisdom that the disorder could be traced to emotional traumas like overly strict toilet training. Dr. Rapoport showed that obsessive-compulsive disorder is not a neurosis, but a neurological disease. She demonstrated that it ran in families, suggesting a biological origin, and she oversaw double-blind drug trials that in 1989 led the Food and Drug Administration to approve the first medication to treat the disorder, Anafranil. “People would stop her on the street and say how much she helped them,” Dr. Francisco X. Castellanos, a child psychiatrist who worked under her, said in an interview. “Her book alerted people that they could get help, that it was not their fault. It was a gigantic leap in science and also in public health.” © 2026 The New York Times Company

Keyword: OCD - Obsessive Compulsive Disorder
Link ID: 30183 - Posted: 04.01.2026

By Andrew Jacobs Over the past two years, Australia, a country long known for its strict drug laws, has been allowing psychiatrists to treat post-traumatic stress disorder with MDMA, the chemical compound better known as Ecstasy or molly. The early results have been striking, researchers say, with more than half of patients who received MDMA along with psychotherapy reporting significant relief from PTSD. Just as notably, Australian drug regulators have not recorded any serious adverse events among the nearly 200 patients who have been through the program, which includes up to three dosing sessions with MDMA, a synthetic stimulant that promotes empathy, emotional connection and feelings of euphoria. That data point is especially relevant given the contentious debate in the United States over the safety of MDMA — one that in 2024 helped sink the prospects for MDMA therapy at the Food and Drug Administration. “Compared to conventional treatments, the outcomes we’re seeing to date with MDMA-assisted therapy have been extraordinary,” said Dr. Ranil Gunewardene, a psychiatrist in Sydney who has treated more than 40 patients since the Australian regulators created a legal pathway for the drug. But Australia’s experiment with psychedelic medicine also highlights the limitations and constraints that the nascent field is likely to face as it gains wider attention from regulators and practitioners. Because Australia is the first country to legalize and regulate MDMA therapy, researchers have been especially eager for real-world data about a drug that has been pejoratively associated with rave culture. © 2026 The New York Times Company

Keyword: Stress; Drug Abuse
Link ID: 30177 - Posted: 03.25.2026

By Christina Caron On the latest season of the HBO Max hospital drama “The Pitt,” a law student named Jackson arrived in the emergency room in a state of psychosis after he “flipped out in the library” and threw a chair at a campus security guard. The news that he might have a mental illness comes as a shock to Jackson’s family, but it soon becomes clear that his break with reality didn’t come out of nowhere. Jackson has been hearing voices for months, viewers learn: “They don’t want me to pass the bar,” he says. “That’s what they told me.” It’s often assumed that psychosis symptoms such as auditory hallucinations and paranoid delusions appear out of the blue. But in reality, most patients with a first episode of psychosis have experienced milder symptoms for months or even years. What’s important, experts say, is recognizing and addressing those symptoms early. “I always tell people if I broke my leg today and got it treated today, it would heal much better than if I waited 18 months,” said Nicholas J. K. Breitborde, director of the Early Psychosis Intervention Center at the Ohio State University Wexner Medical Center. Psychosis is a disruption of the mind’s thoughts and perceptions that causes someone to lose contact with reality. People with psychosis might hear voices, as Jackson did, or see things that other people don’t. They may also have difficulty thinking clearly and may harbor false beliefs, for example the idea that other people are trying to hurt them. Other symptoms include incoherent speech and inappropriate behavior © 2026 The New York Times Company

Keyword: Schizophrenia
Link ID: 30148 - Posted: 03.07.2026

Ian Sample Science editor People with major depressive disorder can see a rapid and lasting improvement after a single dose of the psychedelic drug dimethyltryptamine (DMT) when it is combined with psychotherapy, doctors have said. A small clinical trial involving 34 people found that psychedelic-assisted therapy prompted a swift reduction in depressive symptoms that endured long after the drug had worn off, with some still feeling the benefits six months later. “There is an immediate antidepressant effect that is significantly sustained over a three-month period and that’s exciting because this is one session with a drug, embedded in psychological support,” said Dr David Erritzoe, a psychiatrist at Imperial College London and lead investigator on the trial. Although preliminary, the results add to a growing body of evidence that psychedelic drugs, when coupled with psychotherapy, could help to alleviate depression in the millions of people worldwide who do not respond to existing antidepressants or therapies. An estimated 100 million people worldwide have treatment-resistant depression, defined as a major depressive disorder that has not responded to at least two antidepressants. About half are unable to perform routine daily tasks. The trial, reported in Nature Medicine, focused on people with moderate to severe treatment-resistant depression. One half received a single 21.5mg dose of DMT infused into a vein over 10 minutes. The other half received a placebo infused the same way. All of the participants had psychotherapy and follow-up assessments. © 2026 Guardian News & Media Limited

Keyword: Depression; Drug Abuse
Link ID: 30126 - Posted: 02.18.2026

By Molly Glick Not long after upending federal diet guidelines in order to prioritize “real food” on our plates, United States Health and Human Services Secretary Robert F. Kennedy Jr. has offered a new piece of questionable advice. During a tour to promote these dietary recommendations, Kennedy recently claimed that a keto diet can cure schizophrenia—an assertion that experts have quickly thrown cold water on. The ketogenic diet promotes fat-rich meals and low amounts of carbohydrates. While keto eating has skyrocketed in popularity in recent years—it ranked the most Googled diet in the U.S. in 2020—it was initially designed in the early 20th century for patients with epilepsy. More recent studies have confirmed that the diet is effective for certain types of epilepsy because it can control seizures. Meanwhile, we have much less evidence for its impacts on symptoms of schizophrenia. So far, small studies have offered some early evidence that ketogenic diets may help people with the condition. “There is currently no credible evidence that ketogenic diets cure schizophrenia,” Mark Olfson, a psychiatrist at Columbia University, told The New York Times. Kennedy also proclaimed that the diet can essentially cure bipolar disorder, according to studies he recently read. But as with schizophrenia, keto’s impacts on bipolar disorder have only been examined in limited numbers of patients so far. Preliminary findings have also hinted that a keto diet could ease symptoms of depression. It may offer “small antidepressant benefits” for people who don’t respond to medication, according to a recently published JAMA Psychiatry paper. But this work is in the early stages as well and remains far from conclusive. © 2026 NautilusNext Inc.

Keyword: Schizophrenia; Depression
Link ID: 30109 - Posted: 02.07.2026

By Ellen Barry A new analysis of birth cohorts in the Canadian province of Ontario has found a striking rise in the incidence of psychotic disorders among young people, a finding that its authors said could reflect teens’ increasing use of substances like cannabis, stimulants and hallucinogens. The study, published on Monday in The Canadian Medical Association Journal, found that the rate of new diagnoses of psychotic disorders among people ages 14 to 20 increased by 60 percent between 1997 and 2023, while new diagnoses at older ages plateaued or declined. Compared with people born in the late 1970s, those born in the early 2000s were about twice as likely to have been diagnosed with a psychotic disorder by age 20. The researchers included 12 million people born in Ontario between 1960 and 2009, of which 0.9 percent were diagnosed with a psychotic disorder during the study period. The study was epidemiological and did not try to identify a cause for the rising prevalence. There are a number of possible explanations, among them older paternal age, the stress of migration, neonatal health problems and early intervention programs that now regularly identify the disorders at younger ages, the authors note. But Dr. Daniel Myran, one of the study’s authors, said he undertook the study, in part, to follow up on concerns that the legalization of cannabis might increase population-level rates of schizophrenia and other psychotic disorders. “I was expecting to see some increases in these younger folks, but I was quite surprised by the scale,” said Dr. Myran, a family physician and research chair at North York General Hospital. He said the results suggested a need for more research into the impact of expanding cannabis use by young people. © 2026 The New York Times Company

Keyword: Schizophrenia; Drug Abuse
Link ID: 30106 - Posted: 02.04.2026

By Ellen Barry and Pam Belluck Emily Sliwinski got home from the hospital after giving birth to her first child three years ago, and almost immediately began spiraling. Her thoughts raced; she was unable to sleep; she began hallucinating that her dog was speaking to her. She became obsessed with solving the national shortage of infant formula, covering a corkboard with notes and ideas. About a week later, Ms. Sliwinski, of Greensboro, N.C., went to a hospital emergency room, thinking she would be given medication to help her sleep, she said. She had no history of mental health issues. When doctors decided to commit her for inpatient psychiatric treatment, she became so agitated and fearful that she slapped her mother and her husband. She spent 11 days in the psychiatric hospital, but it didn’t help. “Every day I was trying to figure out where I was and what was happening,” Ms. Sliwinski, 33, recalled. Doctors there did not connect her symptoms to childbirth, she said, and diagnosed her with schizophrenia. It was only when her family got her transferred to a specialized perinatal psychiatric unit at the University of North Carolina at Chapel Hill that doctors zeroed in on the right diagnosis: postpartum psychosis. Ms. Sliwinski’s delayed diagnosis reflects an issue simmering in the highest echelons of American psychiatry. For more than five years, a group of women’s health specialists have been pushing for postpartum psychosis to be listed as a distinct diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, the thousand-page guidebook that influences research funding, medical training and clinical care. But two committees at the apex of the D.S.M. have been split over whether to add it. “Psychiatry’s Bible,” as it is sometimes known, has raised the evidentiary bar for including new diagnoses — only one, prolonged grief syndrome, has been added since 2013. © 2026 The New York Times Company

Keyword: Depression; Hormones & Behavior
Link ID: 30087 - Posted: 01.21.2026

By Andrew Jacobs In the billion-dollar race to commercialize psychedelic medicine, psilocybin, a naturally occurring hallucinogen better known as magic mushrooms, or “shrooms,” has decisively pulled ahead of the pack. The Food and Drug Administration in November said it would move up its review of a psilocybin treatment for severe depression by nine to 12 months, according to the applicant, Compass Pathways. It hopes to receive the agency’s approval for the therapy before the end of the year. The news is among the first concrete signs that the Trump administration is recognizing psychedelic medicine as a potential therapy tool. The moves have injected a fresh dose of optimism into a nascent field, which was rattled by the F.D.A.’s rejection in 2024 of MDMA-assisted therapy, the first psychedelic to reach a formal review by federal regulators. “Between research results and policy changes, it’s a watershed moment for psychedelic health care, and psilocybin is the star,” said Nate Howard, director of operations at InnerTrek, a psilocybin clinic in Portland, Ore. Mr. Howard was a driving force behind a successful ballot measure in 2023 that created Oregon’s psilocybin program. State lawmakers, however, are not waiting for regulators in the nation’s capital. Last year, New Mexico joined Colorado and Oregon in offering legal psilocybin therapy to adults. Lawmakers in a dozen states, including North Carolina, Maryland, Georgia and California, are considering easing restrictions on the drug using public funds to research the potential benefits of psilocybin therapy. © 2026 The New York Times Company

Keyword: Depression; Drug Abuse
Link ID: 30081 - Posted: 01.14.2026

Allison Aubrey If you feel a lift after exercise, you're in good company. Movement can boost mood, and according to the results of a new study, it can also help relieve symptoms of depression. As part of a review of evidence by the Cochrane collaboration — an independent network of researchers — scientists evaluated 73 randomized controlled trials that included about 5,000 people with depression, many of whom also tried antidepressant medication. "We found that exercise was as effective as pharmacological treatments or psychological therapies as well," says Andrew Clegg, a professor at the University of Lancashire in the U.K. The findings are not a surprise to psychiatrist Dr. Stephen Mateka, medical director of psychiatry at Inspira Health. "This new Cochrane review reinforces the evidence that exercise is one of the most evidence-based tools for improving mood," says Mateka. He explains how it mirrors some of the effects of medication. "Exercise can help improve neurotransmitter function, like serotonin as well as dopamine and endorphins. So there is certainly overlap between exercise and how antidepressants offer relief," Mateka says. And there's another powerful effect too. Exercise can trigger the release of brain growth factors, explains Dr. Nicholas Fabiano of the University of Ottawa. He says depression can decrease neuroplasticity, making it harder for the brain to adapt and change. "The brain in depression is thought to be less plastic. So there's less what we call neurotrophic factors, or BDNF," Fabiano explains. He calls it the Miracle-Gro for the brain. "And we know that exercise can also boost it. So I think exercise is a fundamental pillar we really need to counsel patients on," he says. © 2026 npr

Keyword: Depression
Link ID: 30077 - Posted: 01.14.2026

By Diana Kwon edited by Jeanna Bryner By the time Maggie May, an Arkansas resident in her 30s, was admitted to a psychiatric clinic in 2024, she had been struggling for years with atypical anorexia nervosa, an eating disorder that leads to severe food restriction and profound disturbances in body image. (Her name has been changed for privacy.) She had already tried traditional interventions with a psychotherapist and a dietitian, but they had failed to improve her condition. So when May heard about a trial of a new and unconventional therapy, she jumped at the opportunity. The treatment was unusual in that alongside talk therapy, May underwent several sessions in a sensory-deprivation chamber: a dark, soundproof room where she floated in a shallow pool of water heated to match the temperature of her skin and saturated with Epsom salts to make her more buoyant. The goal was to blunt May’s external senses, enabling her to feel from within—focusing on the steady thudding of her heart, the gentle flow of air in and out of her lungs, and other internal bodily signals. The ability to connect with the body’s inner signals is called interoception. Some people are better at it than others, and one’s aptitude for it may change. Life events can also bolster or damage a person’s interoceptive skills. Sahib Khalsa, a psychiatrist and neuroscientist at the University of California, Los Angeles, and his colleagues think a disrupted interoception system might be one of the driving forces behind anorexia nervosa. So they decided to repurpose a decades-old therapy called flotation-REST (for “reduced environmental stimulation therapy”) and launched a trial with it in 2018. They hypothesized that in people with anorexia and some other disorders, an underreliance on internal signals may lead to an overreliance on external ones, such as how one looks in the mirror, that ultimately causes distorted body image, one of the key factors underlying these conditions. “When they’re in the float environment, they experience internal signals more strongly,” Khalsa says. “And having that experience may then confer a different understanding of the brain-body relationship that they have.” © 2025 SCIENTIFIC AMERICAN,

Keyword: Schizophrenia; Anorexia & Bulimia
Link ID: 30067 - Posted: 01.03.2026

By Mattha Busby Bruce Damer had the audience under his Gandalf spell. He was giving a keynote speech in a grand hall at Breaking Convention, a psychedelic-consciousness conference in Exeter, England, in April 2025. Tall and slender, very much bearded, and sporting two large gold hoop earrings, one on either side, Damer looked exactly like you would expect a sexagenarian psychedelic professor to look. A boyishly enthusiastic speaker, he said a psychedelic trip had transported him through time to face a deep trauma. Nautilus Members enjoy an ad-free experience. Log in or Join now . “If you believe in a ‘mother ayahuasca’ or a healing force, I was allowed to experience my conception and birth and be in my mother’s belly,” Damer said. His birth mother had given him up because she and his father were too poor to raise him. Ayahuasca had released him from the pain. “Being in the belly, I could feel her love, and it healed,” he said. “As a result of the clarity and the opening of the blockage that had been this sort of knot in my belly, my whole system opened wide,” Damer continued. “And I thought for a moment, I could potentially travel through time to a place where I’ve been working on the question of how life began, the birth of us all.” In psychedelic science, a field dominated by scientists who are loath to be pigeon-holed as too woo-woo, Damer, 63, has become a cult figure by wearing his woo on his sleeve. His adoptive mother described him as “in his own world” when his new parents brought him home. And he has been his own thinker ever since. His science cred is sound: a Ph.D. in computer science from University College Dublin in Ireland, former relationships with Xerox and NASA, and papers published in journals like Astrobiology. Currently he is a research associate in the Department of Biomedical Engineering at the University of California, Santa Cruz. © 2025 NautilusNext Inc.,

Keyword: Depression; Drug Abuse
Link ID: 30052 - Posted: 12.17.2025

By Alex Kwan Despite decades of basic research, many neurological and psychiatric conditions lack effective treatments, or at least treatments that work for everyone. For that reason, when I talk with colleagues about the value of research, I often hear the same negative refrain: “Basic neuroscience has not produced new drugs.” Their argument carries some weight; many of today’s medications trace their origins to long-standing human use or to chance discoveries. The opium poppy, used for thousands of years to ease pain, paved the way for morphine and other opioids that are widely used as analgesics. Ketamine was designed as an anesthetic but was later unexpectedly revealed to be an antidepressant at low doses. Yet this narrative is incomplete. It overlooks a growing list of medications—including zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—that exist only because of insights from basic research. These drugs were not stumbled upon or borrowed from traditional remedies. They were born out of a long arc of studies in the lab. These success stories matter, because they demonstrate that neuroscience research can deliver new medicines. Acknowledging and publicizing such successes is especially important now, as public funding for basic research in the United States faces growing cuts and restrictions. The development of zuranolone stemmed from an observation about allopregnanolone, a steroid our bodies naturally produce. It has little interaction with steroid receptors and instead acts on GABA receptors in the brain, making neurons less excitable. In the late 1990s, researchers reported that allopregnanolone levels in the rat brain rise dramatically during pregnancy, reaching concentrations of up to three times higher than normal. Just before giving birth, however, the level drops precipitously. © 2025 Simons Foundation

Keyword: Depression; Pain & Touch
Link ID: 30051 - Posted: 12.17.2025

David Shariatmadari In 1973, an American psychologist called David Rosenhan published the results of a bold experiment. He’d arranged for eight “pseudo-patients” to attend appointments at psychiatric institutions, where they complained to doctors about hearing voices that said “empty”, “hollow” and “thud”. All were admitted, diagnosed with either schizophrenia or manic-depressive psychosis. They immediately stopped displaying any “symptoms” and started saying they felt fine. The first got out after seven days; the last after 52. Told of these findings, psychiatrists at a major teaching hospital found it hard to believe that they’d make the same mistake, so Rosenhan devised another experiment: over the next three months, he informed them, one or more pseudopatients would go undercover and, at the end, staff would be asked to decide who had been faking it. Of 193 patients admitted, 20% were deemed suspicious. It was then that Rosenhan revealed this had been a ruse as well: no pseudopatients had been sent to the hospital at all. Not only had doctors failed to spot sane people in their midst; they couldn’t reliably recognise the actually insane. Rosenhan’s gambit seized the public imagination. Were the men in white suits just quacks? Was mental illness even real? Two years later, the film One Flew Over the Cuckoo’s Nest added to the sense of reputational meltdown, and the psychiatric establishment responded with a major tightening up of diagnostic criteria, squeezing disparate symptoms into even tighter boxes. A freewheeling challenge to psychiatry ended up provoking a kind of counter-reformation, making the profession more medicalised than it had been for decades. The whole affair is a neat example of the ideological switchbacks Edward Bullmore maps in his fascinating, personally inflected history of psychiatric ideas. It is all the more mind-boggling – pun intended – when you find out Rosenhan’s paper was largely made up. Research by journalist Susannah Cahalan in 2019 concluded that most of the pseudopatients were invented; one colleague remembered the psychologist as a “bullshitter”. © 2025 Guardian News & Media Limited

Keyword: Schizophrenia
Link ID: 30050 - Posted: 12.17.2025

By Christina Caron When Marjorie Isaacson first started taking medication for depression in her late 20s, she considered it lifesaving. At the time, she had been dealing with a rocky marriage and struggling to eat. The drug, she found, helped her gain equilibrium. “I was really grateful just to be able to function,” she said. But recently, Ms. Isaacson, 69, has been considering whether she wants to stay on antidepressants for the rest of her life. Specifically, Ms. Isaacson wonders about the long-term effects of her medication, a serotonin-norepinephrine reuptake inhibitor that is known to raise blood pressure. And she feels unsettled by the emerging backlash against psychiatric drugs that has condemned their side effects and difficult withdrawal symptoms. “As the years have passed, things have changed from ‘Take it and see how it goes, no need now to be concerned’ to ‘Well, it’s turning out things might be kinda complicated,’” she said. “That is worrisome.” Antidepressants are among the most prescribed and easily accessible drugs in the United States, and many people take them for years. But even though modern-day antidepressants have been around for decades — the Food and Drug Administration approved Prozac for depression treatment in 1987 — there is very little information about long-term use. The F.D.A. approved the drugs based on trials that lasted, at most, a few months, and randomized controlled trials of antidepressants have typically spanned only two years or less. Current clinical guidelines do not specify the optimal amount of time they should be taken for. The lack of data can make it hard for people to know when — or whether — to quit. So we asked psychiatrists: How long should someone stay on antidepressants? © 2025 The New York Times Company

Keyword: Depression
Link ID: 30047 - Posted: 12.13.2025

By Siddhant Pusdekar A single dose of psilocybin leads to widespread network-specific changes to cortical circuitry in mice, according to a new study published today in Cell. The results help explain how psilocybin can bring about lasting changes in behavior, and they pinpoint “the neurons that are most affected,” says Andrea Gomez, assistant professor of molecular and cellular biology at the University of California, Berkeley, who was not involved in the study. Specifically, the psychedelic strengthens cortical inputs from sensory brain areas and weakens inputs into cortico-cortical recurrent loops. Overall, these network changes suggest that psychedelics reroute information in a way that enhances responses to the outside world and reduces rumination, says study investigator Alex Kwan, professor of biomedical engineering at Cornell University. “This study provides some more mechanistic insight for why the drug may be a good antidepressant.” And the rewiring itself is not static, Kwan adds: “It can be influenced by manipulating neural activity” during psychedelic treatment. With this locus of psychedelic-induced changes identified, researchers can unpack how these neuronal ensembles coordinate “to create particular percepts or particular cognitions,” Gomez says. Kwan’s team focused on the mouse dorsal medial prefrontal cortex (dmPFC), which includes the anterior cingulate cortex—an important hub for the serotonin receptors that psilocybin targets. One dose of psilocybin increases dendritic spine growth in the medial prefrontal cortex of mice, an effect that lasts for at least a month, according to a 2021 study by Kwan’s team. And the treatment reduces the animals’ learned stress-related behaviors, but only if pyramidal tract neurons—one of the major types of excitatory neurons in the dmPFC—are active, Kwan’s group reported in April. © 2025 Simons Foundation

Keyword: Drug Abuse; Depression
Link ID: 30042 - Posted: 12.06.2025

By Daniel Bergner Marie began taking fluoxetine, the generic form of Prozac, when she was 15. The drug — an S.S.R.I., a selective serotonin reuptake inhibitor — was part of her treatment in an outpatient program for an eating disorder. It took its toll on her sexuality. “I was in touch with initial sparks of sexual energy relatively young,” she said, remembering crushes as far back as the age of 6 or 7. Shortly before starting on the drug, she was dazzled, from a distance, by a blue-eyed hockey player at school, tall and funny and charismatic. She recalled the fluster and fantasies he stirred. But on the medication, she felt the infatuation vanish swiftly. Listen to this article, read by Eric Jason Martin “And then,” Marie said, “I realized, Oh, I’m not developing new crushes.” She had no clue that the drug might be the cause: “I wasn’t informed about sexual side effects.” Even as the worst of the eating disorder abated, psychiatrists and family doctors told Marie and her parents that she should stay on an antidepressant. She complied, while trying and failing to escape the sexual side effects. She traded fluoxetine for other antidepressants, including Wellbutrin, a different class of antidepressant, which is sometimes prescribed to combat low libido. She’s 38 now and has been off psychiatric medication for six years. But sexual desire remains absent. “For me it’s just an empty dark space,” she said. “There’s nothing there.” Marie told me she has PSSD, post-S.S.R.I. sexual dysfunction, a loss of sexuality that persists after the drug is no longer being taken. It’s a controversial designation, because while the sexual side effects of S.S.R.I.s are well established — depleted or deadened desire, erectile dysfunction for men, elusive arousal for women, delayed and dulled orgasms or the inability to reach orgasm at all — the general assumption is that they subside completely when the drug is no longer in your system. Some psychiatrists suspect that PSSD is actually a result not of repercussions from the drugs but of the problem that led the patient to be medicated in the first place. Depression itself can stymie sexuality. So can anxiety, the other leading reason patients are prescribed S.S.R.I.s. © 2025 The New York Times Company

Keyword: Depression; Sexual Behavior
Link ID: 30006 - Posted: 11.12.2025

By Ramin Skibba In August, two parents in California filed a lawsuit against OpenAI, claiming that the company was responsible for their teenage son’s suicide. The previous fall, according to Maria and Matthew Raine, their 16-year-old, Adam, had started using the company’s popular AI chatbot ChatGPT as a homework helper. Over the course of several months, the Raines alleged, it shifted to a digital companion and then to a “suicide coach,” advising the teen how to quietly steal vodka from his parent’s liquor cabinet, urging him to keep his suicidal ideations a secret, and then guiding him about the feasibility and load-bearing capacity of a noose. By the time of Adam’s death in April, according to the Raines’ complaint, the chatbot had used the word “suicide” 1,275 times, six times more often than Adam himself. The case of Adam Raines was not an isolated incident, though publicly available data remains limited. And experts worry that more mental health crises, including suicides — the second leading cause of death among people between ages 10 and 24 years — could arise as users increasingly turn to generative AI chatbots for emotional support. Although it is difficult to pinpoint just how many people are relying on chatbots in this way, according to a recent Harvard Business Review survey based primarily on data collected from Reddit forum posts, the practice is common for therapy, companionship, and finding purpose. Researchers have scrambled to understand the trend, including both the potential risks and benefits of the chatbots, most of which were not designed to be used for mental health support. Some users claim that the bots help them, citing their perception that the tools won’t judge or stigmatize them, while others are seeking a substitute for therapy when they can’t access or afford it, experts say. Some users also don’t think of the chatbots as a form of therapy, but rather a kind of mindful journaling as they work through their emotions and problems. According to one example in the Harvard Business Review report, a Reddit user said, “I found a thread where people talked about using AI to analyze their moods, essentially having low-barrier ‘therapy’ sessions.

Keyword: Depression
Link ID: 29999 - Posted: 11.05.2025

By Ellen Barry One of the most popular mental health innovations of the past decade is therapy via text message, which allows you to dip in and out of treatment in the course of a day. Say you wake up anxious before a presentation: You might text your therapist first thing in the morning to say that you can’t stop visualizing a humiliating failure. Three hours later, her response pops up on your phone. She suggests that you label the thought — “I’m feeling nervous about my presentation” — and then try to reframe it. She tells you to take a deep breath before deciding what is true in the moment. You read her answer between meetings. “I’m pretty sure my boss thinks I’m an idiot,” you type. The therapist responds the next morning. “What evidence do you have that she thinks that?” she asks. She tells you to write a list of the available evidence, pros and cons. Text-based therapy has expanded swiftly over the past decade through digital mental health platforms like BetterHelp and Talkspace, which pair users with licensed therapists and offer both live chat and as-needed texting sessions. A new study published on Thursday in the journal JAMA Network Open provides early evidence that the practice is effective in treating mild to moderate depression, finding outcomes similar to those of video-based therapy. In a clinical trial, 850 adults with mild to moderate depression were randomly assigned to two groups: One group received psychotherapy via a weekly video session; the other received unlimited, as-needed messaging or emailing with a therapist. After 12 weeks, participants in both groups reported similar improvement in depression symptoms. © 2025 The New York Times Company

Keyword: Depression
Link ID: 29995 - Posted: 11.01.2025